February 9, 2015 | The Israeli company developing drug delivery platforms, SteadyMed Therapeutics filed with the US Securities and Exchange Commission to raise $55 million in a NASDAQ IPO. The company made the move just ten days after raising $12.2 million in equity financing. The reported underwriters for the IPO are Wells Fargo, RBC and JP Morgan. SteadyMed was founded as part of the RAD Biomed incubator. The company is headquartered in San Ramon, California, but a good deal of product development still occurs in Rehovot, Israel. SteadyMed was founded in 2005 and has developed the PatchPump for drug delivery and other novel drug delivery methods.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments